Telehealth Likely to Continue Growing Long After the Public Health Crisis
FN Media Group Presents Microsmallcap.com Market Commentary
News provided by
Share this article
Share this article
NEW YORK, March 8, 2021 /PRNewswire/ The past year has made very clear the value of technology that makes health services available instantly from the comfort of the patient s own home. As the world begins to move on from the public health crisis, the advancements made to the telehealth industry will continue to be valuable, making life easier for patients with limited mobility, helping to reduce the spread of contagious illnesses, and simply reducing the barrier to health services for people with busy lives. The global telehealth industry received a boost in 2020, and is now set to
Psychedelic Stocks Poised to Resume the Upward Trend
News Provided By
Share This Article
Fears of inflation and higher interest rates roiled the market for growth stocks, but the long-term prospects for psychedelic medicine remains bullish
/EIN News/ ATLANTA, Feb. 25, 2021 (GLOBE NEWSWIRE) Fears of inflation and higher interest rates sent the NASDAQ Composite and Russell 2000 lower the past few weeks as many investors ran for cover. Almost as if on command, the same market pundits who were bullish prior to the correction suddenly voiced public concern about the valuations on psychedelic stocks. What they fail to remember is, growth stocks, like those in the psychedelic sector, are almost always considered overpriced by traditional analysis.
Options to consider when requesting an extension to respond to the Patent Office internationallawoffice.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from internationallawoffice.com Daily Mail and Mail on Sunday newspapers.
Mydecine Innovations Group, Inc., is pleased to announce that its subsidiary Mindleap Health a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office and the Canadian Intellectual Property Office. “As our company continues to innovate …
Mydecine Innovations Group, Inc., ( CSE:MYCO ) ( OTC:MYCOF ) ( FSE:0NFA ) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office (USPTO) and the Canadian Intellectual Property Office.
As we previously reported, the Federal Court in
Yves Choueifaty v Attorney General of
Canada, 2020 FC 837 (Choueifaty) granted the appeal from
the Commissioner of Patents (the Commissioner) decision that
Canadian Patent Application No. 2,635,393 (the 393 Application) was
not patentable subject-matter.
On January 11, 2021, the Patent Appeal Board (the Panel)
reconsidered the 393 Application and found that the Second Proposed
Claims, which had been considered by the Court in Choueifaty, were
patentable subject-matter that complied with section 2 of the
Patent Act. The Commissioner agreed with the Panel s
recommendation in
Choueifaty (Re), 2021 CACP 3. This
decision should provide insight to patent applicants regarding how
the Commissioner will apply the Canadian Intellectual Property